President & CEOOfficers of the CorporationBoard of TrusteesFoundation BoardLeadership CouncilAbout Joslin ResearchAdvocacy & Gov't AffairsHistory
Newly DiagnosedManaging DiabetesChildhood DiabetesNutritionExerciseOnline Diabetes ClassesDiscussion BoardsJoslin Clinical ResearchInfo for Healthcare ProfessionalsJoslin Clinical Guidelines
Make an AppointmentmyJoslin Patient PortalAdult ClinicYoung Adult Transition CarePediatricsEye CareWeight Management ProgramsDO ITMental Health & CounselingReferring PhysiciansBillingAfrican American ProgramsAsian ClinicLatino Diabetes InitiativeAbout Joslin ResearchVolunteer for Clinical Research StudiesInfo for Healthcare ProfessionalsClinical Guidelines
Directory of Joslin InvestigatorsDiabetes Research Center Alumni ConnectionVolunteer for Clinical Research Studies
Media RelationsNews ReleasesInside JoslinSocial Media
Affiliated CentersPharma & DeviceCorporate EducationPublicationsProfessional EducationInternationalCause MarketingHealthcare ProfessionalsCommercialization and VenturesJoslin Institute for Technology Translation (JITT)
Give NowHigh Hopes FundWays to GivePlanned GivingEventsGet InvolvedCorporate & Foundation SupportOur DonorsDevelopment Team

News Release

Trigger Found for Autoimmune Heart Attacks

Joslin research may point toward new ways to diagnose and treat heart disease in people with type 1 diabetes

BOSTON – March 23, 2011 – People with type 1 diabetes, whose insulin-producing cells have been destroyed by the body’s own immune system, are particularly vulnerable to a form of inflammatory heart disease (myocarditis) caused by a different autoimmune reaction. Scientists at Joslin Diabetes Center have revealed the exact target of this other onslaught, taking a large step toward potential diagnostic and therapeutic tools for the heart condition.

Researchers in the lab of Myra Lipes, M.D., have shown in both mice and people that myocarditis can be triggered by a protein called alpha-myosin heavy chain, which is found only in heart muscle and in especially low quantities in human heart tissue.

While myocarditis often follows viral attacks or other infections, Dr. Lipes and her colleagues previously demonstrated that mice genetically modified to model type 1 diabetes could generate myocarditis spontaneously.

In their latest work, reported online in the Journal of Clinical Investigation, the scientists analyzed blood from such mice and identified two types of autoimmune response directed specifically against the protein, with the first response directed by a specialized kind of immune system cells called T cells and the second by antibodies.

In both mice and people, T cells are “trained” by specialized cells in the thymus, a small organ in front of the heart, to recognize the body’s own cells and refrain from attacking them. The researchers found, however, that in mice these specialized training cells couldn’t train on the alpha-myosin heavy chain protein because none of that protein was being produced in those cells.

Next, the scientists showed that the disease didn’t develop in similar mice that were genetically engineered to produce the protein in the specialized training cells. “You can totally protect those mice from mortality, which is really extraordinary,” says Dr. Lipes, an Investigator in Joslin’s Section on Islet Cell & Regenerative Biology and an Assistant Professor at Harvard Medical School.

Furthermore, the studies also indicated that alpha-myosin heavy chain was not present in human thymus and that the T cells that sought out the protein could be found in the blood of healthy people. In patients with myocarditis, levels of these cells soared.

The investigation, Dr. Lipes says, suggests that people who are otherwise vulnerable to autoimmune conditions, such as those with type 1 diabetes, may be particularly vulnerable to this risk to their hearts.

Myosin heavy chain proteins are found in two very similar forms in human hearts: alpha-myosin heavy chain, which supports fast muscle contraction and may be particularly prevalent in athlete’s hearts, and beta-myosin heavy chain, which is much more common and functions in slower muscle contraction. “We’re trying to figure ways to identify the fragment of alpha-myosin heavy chain that is different, because that could aid in developing diagnostic tools and therapies,” says Dr. Lipes.

Joslin’s HuiJuan Lv is first author on the paper.  Other contributors include Evis Havari, Raju V. Gottumukkala, Lizbeth Cornivelli and Ross Smith of Joslin; Khadir Raddassi of Brigham and Women’s Hospital; Takashi Matsui and Anthony Rosenzweig of Beth Israel Deaconess Medical Center; Roderick T. Bronson of Harvard Medical School; Anne L. Fletcher, Shannon J. Turley and Kai Wucherpfennig of Dana Farber Cancer Institute; Sheena Pinto and Bruno Kyewski of the German Cancer Research Center.

Lead funders were the National Institutes of Health and the Juvenile Diabetes Research Foundation.